| Phase 11 trial |
|
Phase 1
|
NCT07237425 |
Nov 2025 → Nov 2026 expected |
lipoma |
Glonova Pharma Co., Ltd |
Recruiting
|
No outcome recorded
|
| Phase 43 trials |
|
Phase 4
|
NCT06783621 |
Jan 2025 → Mar 2026 |
— |
AbbVie |
Completed
|
No outcome recorded
|
|
Phase 4
|
NCT04841551 |
Jul 2021 → Mar 2022 |
obesity disorder |
Beer, Kenneth R., M.D., PA |
Completed
|
No outcome recorded
|
|
Phase 4
|
NCT03510598 |
Mar → Dec 2018 |
obesity disorder |
Zeltiq Aesthetics |
Completed
|
No outcome recorded
|
| Comparator or background therapy5 trials |
|
Phase 1
|
NCT06300502 Comparator |
Apr 2025 → Feb 2027 expected |
neurofibroma, neurofibromatosis type 1 |
Massachusetts General Hospital |
Enrolling by invitation
|
No outcome recorded
|
|
Phase 1
|
NCT06120036 Comparator |
Dec 2022 → Jan 2025 |
neurofibromatosis type 1 |
Massachusetts General Hospital |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04730583 Comparator |
Jun 2021 → Apr 2024 |
neurofibroma |
Massachusetts General Hospital |
Completed
|
No outcome recorded
|
|
Phase 4
|
NCT03361176 Comparator |
Mar → Oct 2018 |
obesity disorder |
Goldman, Butterwick, Fitzpatrick and Groff |
Completed
|
No outcome recorded
|
|
Phase 4
|
NCT03241563 Comparator |
Apr 2016 → Feb 2017 |
— |
Goldman, Butterwick, Fitzpatrick and Groff |
Completed
|
No outcome recorded
|